<DOC>
	<DOC>NCT02599402</DOC>
	<brief_summary>The purpose of this study is to determine the effects of combination treatment of Nivolumab with Ipilimumab followed by Nivolumab monotherapy in patients with previously untreated advanced Melanoma.</brief_summary>
	<brief_title>Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Potential subjects must have advanced Melanoma (stage III or IV as confirmed by biopsy) with spread to other sites in the body and unable to be removed by surgery Potential subjects must be newly diagnosed with advanced Melanoma and received no treatment for the advanced disease The subjects who received previous primary treatment and any additional treatment (which is given after the primary treatment) are permitted if it was completed at least 6 weeks prior to study entry and if the side effects of the treatment are resolved If subjects received any of the following primary treatment previously; they are not permitted to be enrolled in the study (antiCTLA4, antiPD1, antiPDL1, antiPDL2, or any other drug specifically targeting Tcell costimulation or checkpoint pathways such as antiCD137) Potential subjects (with disease spread to brain) who previously received primary treatment are permitted if there was no evidence of disease as confirmed by the MRI (at least 2 weeks after the primary treatment is complete and with in 6 weeks of the first dose of the study drug) Potential subjects must not have received intravenous steroid treatment (&gt;10 mg/day) intravenously for at least 2 weeks prior to study drug administration. There is no current (and not previously treated) disease spread to the brain Subjects who received prior therapy with an antiCTLA4, antiPD1, anti PDL1 or antiPDL2, antiCD137 agents (or any other antibody or drug specifically targeting Tcell costimulation or checkpoint pathways) for adjuvant, neoadjuvant, or advanced melanoma treatment or as part of clinical trial Subjects with autoimmune disease. Subjects with Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll All side effects from previous primary treatments other than alopecia, fatigue, or peripheral neuropathy must have resolved to Grade 1 or baseline before administration of study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>